文献速递造血干细胞移植与细胞治疗

匹配供者异基因造血细胞移植后心脏毒性:移植后环磷酰胺时代

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era.
PubMed 文献 · Blood Adv · 2021-01-01

该回顾性分析纳入585例接受匹配供者异基因造血细胞移植的患者,比较移植后环磷酰胺(PTCy)与非PTCy方案预防移植物抗宿主病(GVHD)后100天内心脏毒性的发生情况。结果显示PTCy组心脏毒性发生率为7.4%,非PTCy组为5.8%(P=.4),差异无统计学意义;年龄>55岁及高血压、心律失常、糖尿病、心脏合并症病史是显著预测因素,心脏毒性发生与更差的1年总生存(OS)和非复发死亡(NRM)相关,而PTCy使用与1年OS和NRM改善相关。

要点

  • PTCy与非PTCy方案的心脏毒性发生率分别为7.4%和5.8%,差异无统计学意义。
  • 年龄>55岁及高血压、心律失常、糖尿病、心脏合并症病史是心脏毒性的显著预测因素。
  • 心脏毒性发生与更差的1年OS和NRM相关;PTCy使用与1年OS和NRM改善相关。

核心结论

  • 匹配供者allo-HCT后100天内心脏毒性发生率为6.5%,PTCy与非PTCy方案间无显著差异。
  • 年龄>55岁及高血压、心律失常、糖尿病、心脏合并症病史可预测心脏毒性发生。
  • 心脏毒性发生与更差的1年OS和NRM相关,PTCy使用与1年OS和NRM改善相关。

研究设计与样本

  • 单中心回顾性分析,纳入585例接受匹配供者allo-HCT并接受PTCy或非PTCy方案预防GVHD的患者。
  • 主要目标是确定allo-HCT后100天内心脏毒性的发生率。

主要发现

  • 585例中38例(6.5%)发生心脏毒性,包括心律失常21例、心力衰竭14例、心包积液10例、心肌梗死或缺血7例。
  • PTCy组心脏毒性发生率为7.4%,非PTCy组为5.8%(P=.4)。
  • 年龄>55岁(P=.02)、高血压病史(P=.01)、心律失常病史(P=.003)、糖尿病病史(P=.04)及心脏合并症(P<.001)是心脏毒性的显著预测因素。
  • 预处理方案和GVHD预防方案均不能预测心脏毒性。
  • 较高的心脏风险分层评分与心脏毒性发生率相关。

关键数值与推荐

  • 心脏毒性定义涵盖心律失常、心力衰竭、心包积液、心肌梗死或缺血,观察至移植后100天。
  • 提出心脏风险分层评分用于量化allo-HCT后心脏毒性风险,评分越高心脏毒性发生率越高。

临床怎么用

  • 对年龄>55岁或合并高血压、心律失常、糖尿病、心脏合并症病史的患者,移植前应评估心脏毒性风险。
  • 可考虑使用心脏风险分层评分量化风险并指导监测。
  • PTCy方案未增加心脏毒性风险,且与1年OS和NRM改善相关。

局限性

  • 单中心回顾性分析,可能存在选择偏倚和未测量混杂因素。
  • 心脏毒性事件数较少(38例),统计效能有限。
  • 心脏风险分层评分需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is one of the leading causes of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (allo-HCT). Posttransplant cyclophosphamide (PTCy) has shown promise in managing GVHD. However, cyclophosphamide has known cardiac toxicity, and few studies have evaluated the cardiac toxicities that arise after PTCy. We completed a retrospective analysis of patients who underwent matched-donor allo-HCT at our institution and who received PTCy- or non-PTCy-based GVHD prophylaxis, with the goal of determining the incidence of cardiac toxicities up to 100 days after allo-HCT. We included 585 patients in our analysis and found that 38 (6.5%) experienced cardiac toxicity after allo-HCT. The toxicities included arrhythmias (n = 21), heart failure (n = 14), pericardial effusion (n = 10), and myocardial infarction or ischemia (n = 7). Patients who received PTCy had a 7.4% incidence of cardiac toxicity, whereas non-PTCy recipients had an incidence of 5.8% (P = .4). We found that age >55 years (P = .02) and a history of hypertension (P = .01), arrhythmia (P = .003), diabetes (P = .04), and cardiac comorbidities (P < .001) were significant predictors of cardiac toxicity, whereas none of the preparative and GVHD prophylaxis regimens were predictive. From these findings, we proposed the use of a Cardiac Risk Stratification Score to quantify the risk of cardiac toxicity after allo-HCT. We found that a higher score correlated with an incidence of cardiac toxicity. Furthermore, the development of cardiac toxicity was associated with worse 1-year overall survival (OS) and NRM. The use of PTCy was associated with improvements in 1-year OS and NRM rates.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yeh J, Whited L, Saliba RM, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021. PMID: 34592759. doi:10.1182/bloodadvances.2021004846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。